Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Incidence, prevalence and risk factors for hepatitis C in Danish prisons.

Søholm J, Holm DK, Mössner B, Madsen LW, Hansen JF, Weis N, Sauer AP, Awad T, Christensen PB.

PLoS One. 2019 Jul 26;14(7):e0220297. doi: 10.1371/journal.pone.0220297. eCollection 2019.

2.

Combining liver stiffness with hyaluronic acid provides superior prognostic performance in chronic hepatitis C.

Hansen JF, Christiansen KM, Staugaard B, Moessner BK, Lillevang S, Krag A, Christensen PB.

PLoS One. 2019 Feb 11;14(2):e0212036. doi: 10.1371/journal.pone.0212036. eCollection 2019.

3.

Test uptake and hepatitis C prevalence in 5483 Danish people in drug use treatment from 1996 to 2015: a registry-based cohort study.

Øvrehus A, Nielsen S, Hansen JF, Holm DK, Christensen P.

Addiction. 2019 Mar;114(3):494-503. doi: 10.1111/add.14479. Epub 2018 Nov 25.

PMID:
30347471
4.

Late Presentation for Care Among Patients With Chronic Hepatitis C: Prevalence and Risk Factors.

Hansen JF, Hallager S, Øvrehus A, Weis N, Brehm Christensen P, Pedersen C.

Open Forum Infect Dis. 2017 Nov 22;5(1):ofx257. doi: 10.1093/ofid/ofx257. eCollection 2018 Jan.

5.

Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.

Thiele M, Madsen BS, Hansen JF, Detlefsen S, Antonsen S, Krag A.

Gastroenterology. 2018 Apr;154(5):1369-1379. doi: 10.1053/j.gastro.2018.01.005. Epub 2018 Jan 6.

PMID:
29317276
6.

PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C.

Hansen JF, Juul Nielsen M, Nyström K, Leeming DJ, Lagging M, Norkrans G, Brehm Christensen P, Karsdal M.

Scand J Gastroenterol. 2018 Jan;53(1):83-87. doi: 10.1080/00365521.2017.1392596. Epub 2017 Oct 25.

PMID:
29069995
7.

The flame retardant DE-71 (a mixture of polybrominated diphenyl ethers) inhibits human differentiated thyroid cell function in vitro.

Kronborg TM, Hansen JF, Rasmussen ÅK, Vorkamp K, Nielsen CH, Frederiksen M, Hofman-Bang J, Hahn CH, Ramhøj L, Feldt-Rasmussen U.

PLoS One. 2017 Jun 23;12(6):e0179858. doi: 10.1371/journal.pone.0179858. eCollection 2017.

8.

Projected shifts in fish species dominance in Wisconsin lakes under climate change.

Hansen GJ, Read JS, Hansen JF, Winslow LA.

Glob Chang Biol. 2017 Apr;23(4):1463-1476. doi: 10.1111/gcb.13462. Epub 2016 Sep 8.

PMID:
27608297
9.

Erratum: Reliability Criteria for Liver Stiffness Measurements with Real-Time 2D Shear Wave Elastography in Different Clinical Scenarios of Chronic Liver Disease.

Thiele M, Madsen BS, Procopet B, Hansen JF, Møller LMS, Detlefsen S, Berzigotti A, Krag A.

Ultraschall Med. 2017 Dec;38(6):e51. doi: 10.1055/s-0035-1567110. Epub 2016 Jul 14. No abstract available.

PMID:
27414979
10.

Feasibility of transient elastography versus real-time two-dimensional shear wave elastography in difficult-to-scan patients.

Staugaard B, Christensen PB, Mössner B, Hansen JF, Madsen BS, Søholm J, Krag A, Thiele M.

Scand J Gastroenterol. 2016 Nov;51(11):1354-9. doi: 10.1080/00365521.2016.1193217. Epub 2016 Jun 16.

PMID:
27310486
11.

Reliability Criteria for Liver Stiffness Measurements with Real-Time 2D Shear Wave Elastography in Different Clinical Scenarios of Chronic Liver Disease.

Thiele M, Madsen BS, Procopet B, Hansen JF, Møller LMS, Detlefsen S, Berzigotti A, Krag A.

Ultraschall Med. 2017 Dec;38(6):648-654. doi: 10.1055/s-0042-108431. Epub 2016 Jun 7. Erratum in: Ultraschall Med. 2017 Dec;38(6):e51.

12.

Phthalates Are Metabolised by Primary Thyroid Cell Cultures but Have Limited Influence on Selected Thyroid Cell Functions In Vitro.

Hansen JF, Brorson MM, Boas M, Frederiksen H, Nielsen CH, Lindström ES, Hofman-Bang J, Hartoft-Nielsen ML, Frisch T, Main KM, Bendtzen K, Rasmussen ÅK, Feldt-Rasmussen U.

PLoS One. 2016 Mar 17;11(3):e0151192. doi: 10.1371/journal.pone.0151192. eCollection 2016.

13.

Influence of phthalates on in vitro innate and adaptive immune responses.

Hansen JF, Nielsen CH, Brorson MM, Frederiksen H, Hartoft-Nielsen ML, Rasmussen ÅK, Bendtzen K, Feldt-Rasmussen U.

PLoS One. 2015 Jun 25;10(6):e0131168. doi: 10.1371/journal.pone.0131168. eCollection 2015.

14.

Influence of phthalates on cytokine production in monocytes and macrophages: a systematic review of experimental trials.

Hansen JF, Bendtzen K, Boas M, Frederiksen H, Nielsen CH, Rasmussen ÅK, Feldt-Rasmussen U.

PLoS One. 2015 Mar 26;10(3):e0120083. doi: 10.1371/journal.pone.0120083. eCollection 2015. Review.

15.

Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial.

Winkel P, Hilden J, Hansen JF, Kastrup J, Kolmos HJ, Kjøller E, Jensen GB, Skoog M, Lindschou J, Gluud C; CLARICOR trial group.

Int J Cardiol. 2015 Mar 1;182:459-65. doi: 10.1016/j.ijcard.2015.01.020. Epub 2015 Jan 6.

PMID:
25602299
16.

Liver stiffness measurement among patients with chronic hepatitis B and C: results from a 5-year prospective study.

Christiansen KM, Mössner BK, Hansen JF, Jarnbjer EF, Pedersen C, Christensen PB.

PLoS One. 2014 Nov 4;9(11):e111912. doi: 10.1371/journal.pone.0111912. eCollection 2014.

17.

Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: the CLARICOR trial.

Bjerre M, Hilden J, Kastrup J, Skoog M, Hansen JF, Kolmos HJ, Jensen GB, Kjøller E, Winkel P, Flyvbjerg A, Gluud C; Claricor Trial Group.

Scand J Clin Lab Invest. 2014 Nov;74(8):657-64. doi: 10.3109/00365513.2014.930510. Epub 2014 Jul 15.

PMID:
25026506
18.

Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide.

Lyngbæk S, Winkel P, Gøtze JP, Kastrup J, Gluud C, Kolmos HJ, Kjøller E, Jensen GB, Hansen JF, Hildebrandt P, Hilden J; CLARICOR Trial Group.

Eur J Prev Cardiol. 2014 Oct;21(10):1275-84. doi: 10.1177/2047487313492099. Epub 2013 May 30.

PMID:
23723326
19.

Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial.

Harutyunyan M, Gøtze JP, Winkel P, Johansen JS, Hansen JF, Jensen GB, Hilden J, Kjøller E, Kolmos HJ, Gluud C, Kastrup J.

Immunobiology. 2013 Jul;218(7):945-51. doi: 10.1016/j.imbio.2012.10.015. Epub 2012 Nov 7.

PMID:
23294528
20.

Home-based cardiac rehabilitation is an attractive alternative to no cardiac rehabilitation for elderly patients with coronary heart disease: results from a randomised clinical trial.

Oerkild B, Frederiksen M, Hansen JF, Prescott E.

BMJ Open. 2012 Dec 18;2(6). pii: e001820. doi: 10.1136/bmjopen-2012-001820. Print 2012.

21.

Validation of a turbulent Kelvin-Helmholtz shear layer model using a high-energy-density OMEGA laser experiment.

Hurricane OA, Smalyuk VA, Raman K, Schilling O, Hansen JF, Langstaff G, Martinez D, Park HS, Remington BA, Robey HF, Greenough JA, Wallace R, Di Stefano CA, Drake RP, Marion D, Krauland CM, Kuranz CC.

Phys Rev Lett. 2012 Oct 12;109(15):155004. Epub 2012 Oct 10.

PMID:
23102319
22.

Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial.

Hanash JA, Hansen BH, Hansen JF, Nielsen OW, Rasmussen A, Birket-Smith M.

J Cardiovasc Pharmacol. 2012 Oct;60(4):397-405. doi: 10.1097/FJC.0b013e3182677041.

PMID:
22820898
23.

Why nanoprojectiles work differently than macroimpactors: the role of plastic flow.

Anders C, Bringa EM, Ziegenhain G, Graham GA, Hansen JF, Park N, Teslich NE, Urbassek HM.

Phys Rev Lett. 2012 Jan 13;108(2):027601. Epub 2012 Jan 11.

PMID:
22324707
24.

Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart disease.

Kjoller E, Hilden J, Winkel P, Frandsen NJ, Galatius S, Jensen G, Kastrup J, Hansen JF, Kolmos HJ, Jespersen CM, Hildebrandt P, Gluud C; CLARICOR Trial Group.

J Clin Epidemiol. 2012 Apr;65(4):444-53. doi: 10.1016/j.jclinepi.2011.09.011. Epub 2012 Jan 17.

PMID:
22257841
25.

Effects of escitalopram in prevention of depression in patients with acute coronary syndrome (DECARD).

Hansen BH, Hanash JA, Rasmussen A, Hansen JF, Andersen NL, Nielsen OW, Birket-Smith M.

J Psychosom Res. 2012 Jan;72(1):11-6. doi: 10.1016/j.jpsychores.2011.07.001. Epub 2011 Sep 3.

PMID:
22200516
26.

Self-reported physical inactivity predicts survival after hospitalization for heart disease.

Oerkild B, Frederiksen M, Hansen JF, Prescott E.

Eur J Cardiovasc Prev Rehabil. 2011 Jun;18(3):475-80. doi: 10.1177/1741826710389379. Epub 2011 Feb 9.

PMID:
21450651
27.

High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial.

Harutyunyan MJ, Mathiasen AB, Winkel P, Gøtze JP, Hansen JF, Hildebrandt P, Jensen GB, Hilden J, Jespersen CM, Kjøller E, Kolmos HJ, Gluud C, Kastrup J; CLARICOR Trial Group.

Scand J Clin Lab Invest. 2011 Feb;71(1):52-62. doi: 10.3109/00365513.2010.538081. Epub 2010 Nov 25.

PMID:
21108561
28.

Home-based cardiac rehabilitation is as effective as centre-based cardiac rehabilitation among elderly with coronary heart disease: results from a randomised clinical trial.

Oerkild B, Frederiksen M, Hansen JF, Simonsen L, Skovgaard LT, Prescott E.

Age Ageing. 2011 Jan;40(1):78-85. doi: 10.1093/ageing/afq122. Epub 2010 Sep 15.

PMID:
20846961
29.

Comparison of participants and non-participants in a randomized study of prevention of depression in patients with acute coronary syndrome.

Hansen BH, Hanash JA, Rasmussen A, Hansen JF, Birket-Smith M.

Nord J Psychiatry. 2011 Feb;65(1):22-5. doi: 10.3109/08039488.2010.485326. Epub 2010 May 20.

PMID:
20482462
30.

Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial.

Hilden J, Lind I, Kolmos HJ, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helø OH, Hildebrandt P, Jensen GB, Kastrup J, Kjøller E, Nielsen H, Petersen L, Jespersen CM, Gluud C; CLARICOR Trial Group.

Diagn Microbiol Infect Dis. 2010 Apr;66(4):385-92. doi: 10.1016/j.diagmicrobio.2009.11.011.

PMID:
20226329
31.

Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease.

Jensen GB, Hilden J, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helø OH, Hildebrandt P, Kastrup J, Kolmos HJ, Kjøller E, Lind I, Nielsen H, Petersen L, Jespersen CM, Gluud C; CLARICOR Trial Group.

J Cardiovasc Pharmacol. 2010 Feb;55(2):123-8. doi: 10.1097/FJC.0b013e3181c87e37.

PMID:
19920766
32.

Observation of a Kelvin-helmholtz instability in a high-energy-density plasma on the omega laser.

Harding EC, Hansen JF, Hurricane OA, Drake RP, Robey HF, Kuranz CC, Remington BA, Bono MJ, Grosskopf MJ, Gillespie RS.

Phys Rev Lett. 2009 Jul 24;103(4):045005. Epub 2009 Jul 24.

PMID:
19659365
33.

Mild hyponatremia carries a poor prognosis in community subjects.

Sajadieh A, Binici Z, Mouridsen MR, Nielsen OW, Hansen JF, Haugaard SB.

Am J Med. 2009 Jul;122(7):679-86. doi: 10.1016/j.amjmed.2008.11.033.

PMID:
19559171
34.

Mental disorders and general well-being in cardiology outpatients--6-year survival.

Birket-Smith M, Hansen BH, Hanash JA, Hansen JF, Rasmussen A.

J Psychosom Res. 2009 Jul;67(1):5-10. doi: 10.1016/j.jpsychores.2009.01.003. Epub 2009 Mar 5.

PMID:
19539812
35.

Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial.

Jespersen CM, Kolmos HJ, Frydendall N, Hilden J, Gluud C, Hansen JF; CLARICOR Trial Group.

J Antimicrob Chemother. 2009 Aug;64(2):411-5. doi: 10.1093/jac/dkp190. Epub 2009 May 28.

PMID:
19477891
36.
37.

High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease.

Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, Jespersen CM, Kjøller E, Kolmos HJ, Lind I, Nielsen H, Gluud C; CLARICOR Trial Group.

Eur Heart J. 2009 May;30(9):1066-72. doi: 10.1093/eurheartj/ehp049. Epub 2009 Mar 6.

PMID:
19270316
38.

Dynamic Hohlraums as x-ray sources in high-energy density science.

Hansen JF, Glendinning SG, Heeter RF, Brockington SJ.

Rev Sci Instrum. 2008 Jan;79(1):013504. doi: 10.1063/1.2804765.

PMID:
18248031
39.

Increased ventricular ectopic activity in relation to C-reactive protein, and NT-pro-brain natriuretic peptide in subjects with no apparent heart disease.

Sajadieh A, Nielsen OW, Rasmussen V, Ole Hein H, Hansen JF.

Pacing Clin Electrophysiol. 2006 Nov;29(11):1188-94.

PMID:
17100670
40.

C-reactive protein, heart rate variability and prognosis in community subjects with no apparent heart disease.

Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Hansen JF.

J Intern Med. 2006 Oct;260(4):377-87.

41.

Ventricular arrhythmias and risk of death and acute myocardial infarction in apparently healthy subjects of age >or=55 years.

Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Frederiksen BS, Davanlou M, Hansen JF.

Am J Cardiol. 2006 May 1;97(9):1351-7. Epub 2006 Mar 20.

PMID:
16635610
42.

Measurement of the decay rate of single-frequency perturbations on blast waves.

Edens AD, Ditmire T, Hansen JF, Edwards MJ, Adams RG, Rambo PK, Ruggles L, Smith IC, Porter JL.

Phys Rev Lett. 2005 Dec 9;95(24):244503. Epub 2005 Dec 8.

PMID:
16384385
43.

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial.

Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helø OH, Hildebrandt P, Hilden J, Jensen GB, Kastrup J, Kolmos HJ, Kjøller E, Lind I, Nielsen H, Petersen L, Gluud C; CLARICOR Trial Group.

BMJ. 2006 Jan 7;332(7532):22-7. Epub 2005 Dec 8. Erratum in: BMJ. 2006 Jan 21;332(7534):151.

44.

Prevalence and prognostic significance of daily-life silent myocardial ischaemia in middle-aged and elderly subjects with no apparent heart disease.

Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Hansen JF.

Eur Heart J. 2005 Jul;26(14):1402-9. Epub 2005 Mar 17.

PMID:
15774494
46.
47.

Subchronic inhalation neurotoxicity studies of ethyl acetate in rats.

Christoph GR, Hansen JF, Leung HW.

Neurotoxicology. 2003 Dec;24(6):861-74.

PMID:
14637381
48.

Four-week inhalation toxicity study in rats with nylon respirable fibers: rapid lung clearance.

Warheit DB, Webb TR, Reed KL, Hansen JF, Kennedy GL Jr.

Toxicology. 2003 Nov 5;192(2-3):189-210.

PMID:
14580786
49.

[Rehabilitation after ischemic heart disease].

Jacobsen TN, Hansen JF.

Ugeskr Laeger. 2003 Aug 18;165(34):3225. Danish. No abstract available.

PMID:
12970992
50.

Familial predisposition to premature heart attack and reduced heart rate variability.

Sajadieh A, Rasmussen V, Hein HO, Hansen JF.

Am J Cardiol. 2003 Jul 15;92(2):234-6. No abstract available.

PMID:
12860234

Supplemental Content

Loading ...
Support Center